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Abstract
Background: It is essential that knowledge gained through health services research is collated and made
available for evaluation, for policy purposes and to enable collaboration between people working in similar
areas (capacity building). The Australian Quality Use of Medicine (QUM) on-line, web-based project
database, known as the QUMmap, was designed to meet these needs for a specific sub-section of health
services research related to improving the use of medicines. Australia's National Strategy for Quality Use
of Medicines identifies the primacy of consumers as a major principle for quality use of medicines, and aims
to support consumer led research. The aim of this study was to determine how consumers as a group
have been represented in QUM projects in Australia. A secondary aim was to investigate how the projects
with consumer involvement fit into Australia's QUM policy framework.
Method:  Using the web-based QUMmap, all projects which claimed consumer involvement were
identified and stratified into four categories, projects undertaken by; (a) consumers for consumers, (b)
health professionals for consumers, (c) health professionals for health professionals, and (d) other.
Projects in the first two categories were then classified according to the policy 'building blocks' considered
necessary to achieve QUM.
Results: Of the 143 'consumer' projects identified, the majority stated to be 'for consumers' were either
actually by health professionals for health professionals (c) or by health professionals for consumers (b)
(47% and 40% respectively). Only 12 projects (9%) were directly undertaken by consumers or consumer
groups for consumers (a). The majority of the health professionals for consumers (b) projects were
directed at the provision of services and interventions, but were not focusing on the education, training
or skill development of consumers.
Conclusion: Health services research relating to QUM is active in Australia and the projects are collated
and searchable on the web-based interactive QUMmap. Healthcare professionals appear to be dominating
nominally 'consumer focussed' research, with less than half of these projects actively involving the
consumers or directly benefiting consumers. The QUMmap provides a valuable tool for policy analysis and
for provision of future directions through identification of QUM initiatives.
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Background
Many of the findings of health services research are never
published in peer-reviewed journals nor presented at a
conference [1,2]. There may be many reasons for this,
including that such projects are often small, the research-
ers often hold clinical or service positions and their
research time is minimal or non-existent, or the results did
not eventuate 'as intended' [1]. A lot of potential 'lessons
learned' are lost to future researchers, there is a risk that an
unsuccessful study may be replicated, the researchers
themselves lose an opportunity to make contact with
other researchers with similar interests or similar studies,
and input into policy direction or development is lost [2].
Opportunities for capacity building by teams linking up
together are also lost. As discussed below, the quality use
of medicines (QUM) on-line project database, known as
the QUMmap [3], seeks to address some of these issues
and provide decision makers with an interactive, accessi-
ble web-based database to search for previous and on-
going QUM initiatives.
Initiatives to improve use of medicines are being imple-
mented around the world in an effort to maximise health
outcomes, reduce adverse events and keep health costs
within affordable limits. While prescribing behaviour is
one factor that can be targeted to improve use of medi-
cines, it is widely acknowledged that consumer behaviour
also influences medication use and that involvement of
consumers in strategies to improve use of medicines is
necessary in any country's attempts to promote rational
drug use [4].
Australia has a comprehensive strategy for promoting
rational drug use, known as the National Strategy for
QUM [5]. A key principle of the strategy is the primacy of
consumers in any initiative to promote quality use of
medicines. Another key principle is that multidisciplinary,
collaborative approaches are necessary to improve use of
medicines and that these approaches should involve all
stakeholder groups (ie. doctors, nurses, pharmacists, con-
sumers etc) from the beginning of an initiative's develop-
ment. This has demonstrated effectiveness particularly in
the modification of drug use. [6,7] A WHO publication on
developing and implementing national drug policies
stated the importance of consumers in improving use of
medicines [4].
To assist in evaluating the implementation of the
National Strategy for Quality Use of Medicines, the QUM
Mapping Project was commissioned by the Australian
Department of Health and Ageing, in conjunction with
the Pharmaceutical Health and Rational use of Medicines
(PHARM) committee [2]. The aim was to set up a database
of QUM projects and initiatives in Australia. The mapping
Levels of the QUM pyramid – the faces of the three dimensional pyramid representing all the partners required to achieve  optimal quality use of medicines (consumers, government, health professionals, industry) Figure 1
Levels of the QUM pyramid – the faces of the three dimensional pyramid representing all the partners required to achieve 
optimal quality use of medicines (consumers, government, health professionals, industry). Adapted from the National Strategy 
for Quality Use of Medicines – Plain English Edition [8]
Level 3
Level 1 
Level 3:  The action and evaluation level 
Knowledge, skills and resources needed to achieve 
quality use of medicines.  It involves issues of 
monitoring positive and adverse effects, quality 
assurance and problem solving 
Level 1:  The awareness level 
Awareness of medicines as a health issue. 
Prepared to contemplate changes at an 
individual or population level. 
Level 2:  The knowledge and skills level 
Knowledge, skills and resources needed to make 
appropriate decisions at a personal, interpersonal 
and population level.  Ready to take action    Level 2
Level 2:  The knowledge and skills level 
Knowledge, skills and resources needed to make 
appropriate decisions at a personal, interpersonal 
and population level.  Ready to take action    Level 2BMC Health Services Research 2005, 5:75 http://www.biomedcentral.com/1472-6963/5/75
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project website has been on-line since February 1999, and
has collected over 1000 reports of QUM projects in Aus-
tralia.
The approach to improving medicine use in Australia is
often referred to as a systems approach, indicating that
behaviours to support quality use of medicines must be
developed, while at the same time a supportive environ-
ment must be created. In developing appropriate behav-
iours, there is a need to implement initiatives that raise
awareness of quality use of medicines as an issue, that
develop appropriate skills and knowledge, and that rein-
force and maintain appropriate behaviours [8]. This is
conceptualised as Figure 1. The National Strategy identi-
fies six 'building blocks' as essential components to
achieve optimal quality of medicine use, raising levels of
awareness and action across all sectors;
• Policy development and implementation;
• Facilitation and co-ordination of quality use of medi-
cines initiatives;
• Provision of objective information and assurance of eth-
ical promotion of medicines;
• Education and training;
• Provision of services and appropriate interventions; and
• Strategic research, evaluation and routine data collec-
tion.
This strategy also has international relevance, as the
health care systems of many countries strive to improve
the use of medications and to increase consumer involve-
ment in this process [9-11].
The consumer movement in Australia was a driving force
behind the establishment of the National Strategy for
Quality Use of Medicines and Australia's National Medi-
cines Policy. In 1988, the Consumers Health Forum of
Australia circulated a discussion paper, entitled "Develop-
ing a rational medicinal drug policy for Australia – What
does it mean?" [12]. This document was published in its
newsletter and distributed to Commonwealth, State and
Territory governments, and to the organisations which
represented pharmacists, medical practitioners, the phar-
maceutical industry, clinical pharmacologists, alcohol
and drug societies and patient support groups. In 1989,
the Consumers Health Forum of Australia moved the
process forward again when they produced a report enti-
tled "Towards a National Medicinal Drug Policy" [13].
This identified a number of components considered, from
a consumer perspective, to be essential within a national
medicines policy. The lack of any overall policy on quality
medication use was noted. In addition, maintaining serv-
ices developed by and for consumers was seen as an
important component of any national strategy. The
implementation of Australia's National Strategy for Qual-
ity Use of Medicines, which began in 1992, was supported
with approximately $2 million annually in research fund-
ing. This research funding was available to all groups and
aimed to ensure multidisciplinary research, which
included consumer involvement from project conceptual-
isation. There were also efforts to support consumer led
research so that services and resources appropriate to con-
sumer needs for improving use of medicines were devel-
oped. More recently, Australia's National Health and
Medical Research Council have published a statement on
consumer and community participation in health and
medical research [14]. Consumer involvement in research
has also been investigated using surveys and question-
naires to determine the nature and extent of their involve-
ment in funding bodies and in randomised clinical trials
[15,16].
Objectives
The main aim of this study was to evaluate how consum-
ers, as a group, have been represented in the QUM
projects in Australia. A secondary aim was to investigate
how these projects relate to the QUM policy framework,
in particular, to the six key QUM building blocks defined
by Australia's National Strategy for QUM.
Methods
Using the standard SQL search engine available on the
QUMmap [3], all projects were identified which either
claimed that "consumers" were the target group (this is a
tick box available as one choice when projects are entered
on the database) or included a text word "consumer". The
term "consumer" is widely used in reference to healthcare
in Australia and has a broad definition to include any user
or potential user of health care [17]. The QUMmap has
this group noted as a specific tick box target group. The
search was undertaken to be as inclusive as possible of all
research involving consumers in any way, for consulta-
tion, for collaboration or as initiators of the research. The
database search was undertaken for the period February
Table 1: Categories of projects on the QUMmap identifying 
consumers as their target, or having consumer as a searchable 
term
Category Number Percent
Health professionals for consumers (b) 69 47
Health professionals for health professionals (c) 57 40
Consumers for consumers (a) 12 9
Other (d) 5 4BMC Health Services Research 2005, 5:75 http://www.biomedcentral.com/1472-6963/5/75
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1999 and December 2004 using the publicly accessible
searching facilities provided on the website [3].
All identified projects were evaluated and sorted into four
groups by CK, in consultation with ER and ST, using defi-
nitions as follows:
(a) Consumers for consumers – any consumer or con-
sumer group undertaking research/initiatives directly for
consumers;
(b) Health professionals for consumers – health profes-
sionals (doctors, nurses, pharmacists etc) undertaking
research/initiatives which directly involve consumers as
part of the initiative (eg health professionals working with
consumer groups to provide educational material);
(c) Health professionals for health professionals – a QUM
research project/initiative undertaken by health profes-
sionals to improve health professional services which may
indirectly provide assistance to the consumer.
(d) Other – does not fit into any of these categories,
although consumers had been nominated as a target
group or the term consumer was included in the project
description.
Categories (c) and (d) were discarded from further analy-
sis because they did not involve consumers directly in
QUM activities or research. This left the consumer for con-
sumer for consumer (n = 12) (category (a)) and health
professional for consumer (n = 69) (category (b)) projects
(n = 81, total). These remaining projects were then allo-
cated by CK, in consultation with ER and ST, to one of the
three levels of the QUM pyramid (Figure 1) [8] and ana-
lysed to see which level the projects were achieving in the
QUM framework. They were also allocated to one of the
six key building blocks of Australia's QUM strategy [8]. A
Kruskal-Wallis test was used (difference considered signif-
icant if P < 0.05) to investigate differences between project
costs in the categories, where these were recorded.
Results
In the period from February 1999 to December 2004, 143
projects on the QUMmap [3] were identified by the search
strategy. However, the majority of projects stated to be for
consumers, were either undertaken by health profession-
als for health professionals (category (c)) or health profes-
sionals for consumers (category (b)). Only 12 projects
could be identified as being directly undertaken by con-
sumers or consumer groups specifically for consumers
(category (a)) (Table 1).
The geographical distribution of projects sorted by catego-
ries (a), (b) and (c) is presented in Table 2. The majority
of projects in the consumers for consumers (a) category
were undertaken in the state of New South Wales (8/12),
Australia's most populous state where many head offices
of consumer organisations are found. Five projects were
undertaken by the Australian Pensioners' & Superannu-
ants' Federation, one by the Council of the Aging, and one
by the Combined Pensioners and Superannuants Associa-
tion.
The median cost of the 9 consumers for consumers (cate-
gory (a)) projects for which funding data were available
was AUD $59,000 (range 26,000 – 240,000). This was
similar to the median cost of $57,000 for health profes-
sionals for consumers (category (b)) projects (n = 45 with
funding data available; range $400 – $668,000). The
median cost for health professionals for health profes-
sionals (category (c)) projects was AUD $83,000 (n = 27
with funding data available, range $5,000 – $392,000).
These were not statistically significantly different (P =
0.18).
The QUM pyramid levels for the health professionals for
consumers (category (b)) and the consumers for consum-
ers (category (a)) projects are presented in Table 3. Most
Table 2: State distribution of selected categories of project on the QUM Map
Number (%)
State Consumers for consumers (a) Health professionals for 
consumers (b)
Health professionals for health 
professionals (c)
NSW 8 (67) 17 (25) 18 (32)
SA 1 (8) 17 (25) 15 (26)
VIC 2 (17) 12 (17) 7 (12)
ACT - 5 (7) 4 (7)
QLD - 8 (12) 9 (16)
WA - 7 (10) 3 (5)
TAS - 2 (3) 1 (2)
NT 1 (8) 1 (1) -BMC Health Services Research 2005, 5:75 http://www.biomedcentral.com/1472-6963/5/75
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of the consumers for consumers (category (a)) projects
were about informing or educating consumers about
QUM, with a small number of projects introducing skill
levels to make appropriate QUM decisions. In compari-
son, the health professionals for consumers (category (b))
projects covered all levels of the QUM pyramid. It is inter-
esting to note that more of the health professionals for
consumers (category (b)) projects were located in the
upper part of the pyramid, with a greater focus on action
and evaluation.
Analysis of the projects according to the QUM building
block classification demonstrated that the majority of
health professionals for consumers (category (b)) projects
were about the provision of services and interventions.
The health professionals for consumers (category (b))
projects did not focus on education and training or build-
ing skill development in consumers.
Discussion
This paper audits the consumer role in QUM projects
listed on the Australian QUM Map, asking the question,
are consumers adequately involved in the QUM activities
in Australia? One hundred and forty three projects that
claimed to involve "consumers" were identified using the
searches readily available on the QUM map website [3].
Only 81 (57%) of these projects involved consumers
either via consumer groups, or with some interaction with
healthcare professionals to provide direct benefit to the
consumer. Furthermore, only 12 (9%) were projects
undertaken by consumers for consumers. The majority of
the consumers for consumers projects have been under-
taken in New South Wales, with Victoria being the next
most prominent state. New South Wales and Victoria are
Australia's most populated states.
A number of health professional projects (n = 69) are
involving consumers (health professionals for consumers
(category (b)) projects), with good distribution among all
states of Australia. All projects that receive funding by the
major supporting bodies for QUM in Australia are cur-
rently included on the QUMmap (more details of the
projects included and the policy potential for the map
have been published previously [2]). The data currently
on the QUMmap can be considered to be a sample of
projects undertaken in the QUM area in Australia, with
the current audit showing a "snap-shot" of the spread of
activity.
It would appear that health professionals for health pro-
fessionals projects are receiving greater median funding
per project than those directly involving consumers
($83,000 versus $57,000 median funding for health pro-
fessionals for consumers or versus $59,000 median for
consumers for consumers), although these differences
were not statistically significant (P = 0.18, comparison of
the three categories). Perhaps the level of expertise associ-
ated with grant applications by health professionals con-
trasted to those made by consumers or consumer groups.
It could also be that project budgets are formulated differ-
ently, depending upon which partners are involved.
Evaluation using the levels of the QUM pyramid of the
consumers for consumers (category (a)) and health pro-
fessionals for consumers (category (b)) projects has
shown some interesting trends. The consumers for con-
sumers projects are mostly based at the bottom of the pyr-
amid (information/awareness) with some in the middle
sections endeavouring to increase awareness and prepare
consumers to take action on QUM. In contrast, the health
professionals for consumers projects are in the top two
thirds of the pyramid – ready to take action and actively
monitoring adverse and positive effects of QUM. In addi-
tion consumer projects, including those undertaken by
health professionals are narrowly focused within the key
building blocks, directed mainly to the provision of serv-
ices and interventions. More activity across all the essen-
tial domains of Australia's QUM National Strategy is
clearly required. Consumers (or consumer groups) need
to be encouraged via financial, infrastructure or other
means, to develop QUM projects that move into the
upper echelon of the QUM pyramid and cover all key
building blocks.
It is important that consumers are directly involved in all
aspects of the QUM process in order to achieve successful
behaviour change. It is well recognised that health profes-
sionals, by not directly involving consumers/consumer
Table 3: QUM pyramid level as defined in Australia's National Strategy for Quality Use of Medicines (QUM) for selected projects on 
the QUMmap
QUM Pyramid level
Raising awareness Knowledge and skill development Reinforcement and maintenance
Consumers for consumers (a) 8 4 0
Health professionals for 
consumers (b)
24 20 25BMC Health Services Research 2005, 5:75 http://www.biomedcentral.com/1472-6963/5/75
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groups may be perceived as "paternalistic", the outcome
being that consumers are resistant to being peripherally
involved in activities or are resistant to changing their use
of medicines [18-21]. Indeed, it has been shown that
involvement of consumer and community groups early in
projects improves uptake by consumers, and this has been
demonstrated particularly in projects involving the use of
sunscreens, cancer screening programs, smoking cessation
programs, and in the treatment of asthma [21-26]. More-
over, we found no projects designed and implemented by
consumers for health care professionals.
Although other countries do not have specific QUM strat-
egies or even defined National Medicines Policies includ-
ing QUM, the messages presented here for Australia can
be taken and developed in other health care systems inter-
nationally. Increasing consumer led initiatives is impor-
tant in all countries [15,16]. The projects audited by this
study are available for international perusal on the QUM-
map and the QUMmap, or a similar database would be a
valuable addition to the health services research effort of
other countries. Canada has recently developed a similar
database [27].
The major limitation of this present audit is that the
QUMmap may not capture all QUM research and projects
implemented in Australia. However it does include all
those that are funded by General Practice Education Pro-
gramme (GPEP), QUM Evaluation Programme
(QUMEP), National Health and Medical Research Coun-
cil (NHMRC), Pharmacy Government Agreements, the
National Prescribing Service (NPS) and the Safety and
Quality Council. It has also achieved wide publicity such
that many projects are entered by the investigators them-
selves [2]. Although this website has been advertised
widely through academic, professional and other inter-
ested bodies, it is possible that some consumer based
QUM projects have not been entered on to the database
and therefore have not been included in this audit. The
significance of the lack of mandatory reporting of QUM
projects on the QUMmap has been highlighted previously
[1]. Costings were included only for some projects, which
limits the interpretation of the findings and statistical
analyses of median funding for the different categories of
projects. The projects were classified by CK, in consulta-
tion with ER and ST as consensus classifications. Although
independent ratings and reliability analyses were not con-
ducted, we consider that the classification system was
clear and that misclassifications were unlikely.
Conclusion
This audit of the QUMmap would indicate that consum-
ers as a group are not well represented in QUM research in
Australia, with some states having no consumer driven
projects on the QUMmap. Healthcare professionals
appear to be dominating consumer based research, with
only a little over half of these projects actively involving
the consumers or directly benefiting consumers. On this
basis, consumers (or consumer groups) need to be
encouraged via financial, infrastructure or other means, to
develop or be directly involved in the QUM projects in all
states of Australia. It is likely that similar conclusions
could apply to other health care systems internationally.
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